178 results
Page 5 of 9
6-K
EX-99.1
al8 r8jgqsnmgf
1 Jun 21
Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy
8:02am
6-K
EX-99.2
gqb2mqa iujt2ho
28 May 21
Condensed Consolidated Financial Statements
4:33pm
6-K
EX-99.1
8lqs59myyd78 kegti6x
18 May 21
Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis
8:03am
6-K
EX-99.1
9lcv3yfe
22 Mar 21
Report of Foreign Private Issuer
8:02am
6-K
EX-99.1
ld1a1ej96eg9flnag54
8 Mar 21
Enlivex Receives Notice of Allowance for Japanese Patent Application
8:03am
6-K
EX-99.1
az81hsgd5nz7o
1 Mar 21
Report of Foreign Private Issuer
7:58am
6-K
EX-99.1
gxlgpug
22 Feb 21
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy
8:04am
6-K
EX-99.1
3c3fy9gr3y4dn r4rwz
18 Feb 21
Enlivex Announces Exercise of Underwriter’s Option to Purchase Additional Shares
8:03am
6-K
EX-99.1
kvp4iqkh21 0ysozio
16 Feb 21
Current report (foreign)
8:30am
6-K
EX-1.1
vo9xqenibsne
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
6-K
EX-99.1
ze7in59wm3d2 lebc66
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
424B5
note3 vjq
10 Feb 21
Prospectus supplement for primary offering
5:22pm
FWP
j0lz83b dv3
10 Feb 21
Free writing prospectus
6:08am
FWP
vj0wqh y1wlgas4mc1u
9 Feb 21
Free writing prospectus
5:21pm
424B5
epfi8j
9 Feb 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-99.1
9zo5c2s prmsz8w
3 Feb 21
Current Report
7:55am
6-K
EX-99.1
darsx rwkxxwc
21 Dec 20
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
8:02am
6-K
EX-99.1
rfu3rwkt49ig53m2m
7 Dec 20
Enlivex Announces Issuance of New Chinese Patent Covering Allocetra Immunotherapy
8:02am
6-K
EX-99.1
9pf00a150101p5za72di
3 Dec 20
Enlivex Reports Positive Interim Results From Phase II Clinical Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients
8:00am